SANKYO, SANTEN PHARMACEUTICAL TO COLLABORATE IN DEVELOPING DRY EYE TREATMENT

Sankyo and Santen Pharmaceutical have signed a licensing agreement on CS-011 (rivoglitazone), Sankyo's proprietary agent designed for the treatment of diabetes. Under the agreement terms, the two companies will strive to develop a solution that uses CS-011 to act directly on corneal epithelial cells and improve dry eye symptoms. Specifically, Sankyo will manufacture and supply CS-011 to Santen while Santen will be in charge of development, production and sales of the new solution. In addition, the two companies will collaborate in sales in Japan.

Japan Corporate News Network (http://www.japancorp.net/Article.Asp?Art_ID=11007)